Answers are grounded in this paper and cite their sources.
OBJECTIVE: Adolescent obesity remains a major clinical challenge, with limited effective treatment options beyond lifestyle modification. Liraglutide, a glucagon-like peptide-1 receptor agonist approved for adolescents aged ≥ 12 years, has shown promising results in clinical trials; however, real-world data remain scarce. This study aimed to evaluate the real-world effectiveness and tolerability of liraglutide in adolescents with severe obesity, including weight, body composition, and metabolic outcomes. METHODS: This retrospective longitudinal cohort study included adolescents with obesity aged 12-19 years who received liraglutide therapy. Anthropometric, biochemical, body composition, and adverse event data were assessed monthly. RESULTS: A total of 29 adolescents with obesity (13 males) were included (mean age: 15.7 ± 2.0 years; mean body mass index (BMI): 38.6 ± 6.0 kg/m2; body mass index standard deviation score (BMI-SDS): 3.38 ± 0.57). - BMI-SDS decreased progressively, with an estimated reduction of 0.46 from baseline to month 6; the decline was numerically faster in the first 3 months than in months 3-6, without reaching statistical significance (P = .11). Lean mass percentage increased and total fat percentage decreased after 3 months (both P < .05). Total cholesterol, fasting insulin, and homeostasis model assessment of insulin resistance decreased significantly, while other metabolic parameters remained unchanged. Gastrointestinal adverse events were common; 3 patients discontinued due to intolerance and 1 due to gallstones. CONCLUSION: In this real-world cohort, liraglutide treatment was associated with early and clinically meaningful reductions in BMI-SDS and improvements in insulin sensitivity in adolescents with severe obesity. The therapy was generally well tolerated, though gastrointestinal side effects and financial barriers limited treatment persistence. Longer-term prospective studies are needed to assess durability and cardiometabolic outcomes.
No takes yet. Share an insight, caveat, or question.
Karakaş et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: